非唑奈坦对绝经所致血管舒缩症状健康相关生活质量的影响:SKYLIGHT 1和SKYLIGHT 2随机对照试验的汇总数据
基于SKYLIGHT 1和2预先设定的汇总分析,纳入1022名40-65岁伴中重度血管舒缩症状的女性,随机接受安慰剂或非唑奈坦30或45 mg每日一次治疗12周。非唑奈坦45 mg较安慰剂在第4周和第12周降低MENQoL总分,30 mg降幅相似,MENQoL各领域评分和工作生产力损害均有改善,非唑奈坦组报告血管舒缩症状「好得多」的人数约为安慰剂组的两倍。
要点
- 非唑奈坦45 mg较安慰剂降低MENQoL总分第4周-0.57(95%CI -0.75至-0.39),第12周-0.47(95%CI -0.66至-0.28)。
- 非唑奈坦30 mg的MENQoL总分降幅与45 mg相似。
- 非唑奈坦组基于PGI-C VMS评估报告症状「好得多」的女性人数约为安慰剂组的两倍。
核心结论
- 非唑奈坦治疗与MENQoL测量的整体生活质量改善及WPAI-VMS测量的工作生产力改善相关,高比例接受非唑奈坦者基于PGI-C VMS应答分析认为血管舒缩症状「好得多」。
研究设计与样本
- SKYLIGHT 1和SKYLIGHT 2研究的预先设定汇总分析,地点为美国、加拿大、欧洲,时间为2019-2021年。
- 纳入1022名年龄≥40至≤65岁、伴中重度血管舒缩症状(每日最少平均7次潮热)且寻求治疗的女性。
- 女性随机接受12周双盲治疗,每日一次安慰剂或非唑奈坦30或45 mg;完成者进入40周主动扩展期,非唑奈坦组继续原剂量,安慰剂组重新随机接受非唑奈坦30或45 mg。
主要发现
- 非唑奈坦45 mg较安慰剂降低MENQoL总分,第4周为-0.57(95%CI -0.75至-0.39),第12周为-0.47(95%CI -0.66至-0.28)。
- 非唑奈坦30 mg的MENQoL总分降幅与45 mg相似。
- MENQoL各领域评分亦降低,WPAI-VMS评分改善。
- 基于PGI-C VMS评估,接受非唑奈坦者报告血管舒缩症状「好得多」的人数为安慰剂组的两倍。
关键数值与推荐
- 主要结局指标为基线至第4周和第12周MENQoL总分及各领域评分、WPAI-VMS领域评分、PGI-C VMS的平均变化,以及达到PGI-C VMS「好得多」(PGI-C VMS应答者)的百分比。
- 平均降幅采用混合模型重复测量协方差分析估计。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effect of fezolinetant treatment on health-related quality of life using pooled data from SKYLIGHT 1 and 2 studies. DESIGN: Prespecified pooled analysis. SETTING: USA, Canada, Europe; 2019-2021. POPULATION: 1022 women aged ≥40 to ≤65 years with moderate-to-severe vasomotor symptoms (VMS; minimum average seven hot flushes/day), seeking treatment for VMS. METHODS: Women were randomised to 12-week double-blind treatment with once-daily placebo or fezolinetant 30 or 45 mg. Completers entered a 40-week, active extension (those receiving fezolinetant continued that dose; those receiving placebo re-randomised to fezolinetant received 30 or 45 mg). MAIN OUTCOME MEASURES: Mean changes from baseline to weeks 4 and 12 on Menopause-Specific Quality of Life (MENQoL) total and domain scores, Work Productivity and Activity Impairment questionnaire specific to VMS (WPAI-VMS) domain scores, Patient Global Impression of Change in VMS (PGI-C VMS); percentages achieving PGI-C VMS of 'much better' (PGI-C VMS responders). Mean reduction was estimated using mixed model repeated measures analysis of covariance. RESULTS: Fezolinetant 45 mg mean reduction over placebo in MENQoL total score was -0.57 (95% confidence interval [CI] -0.75 to -0.39) at week 4 and -0.47 (95% CI -0.66 to -0.28) at week 12. Reductions were similar for 30 mg. MENQoL domain scores were also reduced and WPAI-VMS scores improved. Twice as many women receiving fezolinetant reported VMS were 'much better' than placebo based on PGI-C VMS assessment. CONCLUSIONS: Fezolinetant treatment was associated with improvement in overall QoL, measured by MENQoL, and work productivity, measured by WPAI-VMS. A high proportion receiving fezolinetant felt VMS were 'much better' based on PGI-C VMS responder analysis.
引用
- Cano A, Nappi RE, Santoro N, et al. Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials. BJOG. 2024. PMID: 38320967. doi:10.1111/1471-0528.17773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。